Personalized Medicine Market 2020 Research Report by Size, Revenue, Opportunities, COVID-19 Impact, Status and Outlook to 2024 | Absolute Reports

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

Global “Personalized Medicine Market” forecast 2020-2024 is a historical overview and in-depth study on the present and upcoming market of the Personalized Medicine industry. The report represents a basic overview of the Personalized Medicine market size, share, and competitor segment with a basic introduction of manufactures, geographical regions, product types, and applications. This report gives a historical overview of the Personalized Medicine market trends, growth, revenue, capacity, cost structure, and key driver’s analysis.

About Personalized Medicine:

Individualized medication, medication “vary from person to person” , give full consideration to each patient’s genetic factors, gender, age, body weight, physiological and pathological characteristics, and are taking other drugs on the basis of the comprehensive situation of safe, reasonable, effective and economic drug treatment.

Get a Sample Copy of the Report – https://www.absolutereports.com/enquiry/request-sample/14684359

Personalized Medicine Market Segment by Manufacturers, this report covers:

● Abbott Laboratories ● Agilent Technologies ● Amgen ● Astellas Pharma ● Astrazeneca ● Bayer AG ● Celgene Corporation ● Glaxosmithkline Plc ● Illumina ● Johnson and Johnson ● Laboratory Corporation ● Merck ● Novartis AG ● Roche Holding AG ● Siemens AG ● Takeda Pharmaceutical Company Limited

Market Segment by Regions, regional analysis covers:

● North America (United States, Canada and Mexico) ● Europe (Germany, France, UK, Russia and Italy) ● Asia-Pacific (China, Japan, Korea, India and Southeast Asia) ● South America (Brazil, Argentina, Colombia etc.) ● Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

● Personalized Medicine Diagnostics ● Personalized Medical Care ● Personalized Medicine Therapeutics ● Personalized Nutrition and Wellness

Market Segment by Applications, can be divided into:

● Oncology ● Central Nervous System (CNS) ● Immunology ● Respiratory ● Other Applications ● Personalized MedicinePersonalized Medicine

To Understand How Covid-19 Impact Is Covered in This Report – https://www.absolutereports.com/enquiry/request-covid19/14684359

Scope of this report:

● The global Personalized Medicine market is expected to reach significant USD by the end of 2024. ● The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. ● North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Personalized Medicine. ● Europe also play important roles in global market, with market size of significant USD in 2019. ● This report studies the Personalized Medicine market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Personalized Medicine market by product type and applications/end industries.

The content of the study subjects includes a total of 15 chapters:

● Chapter 1, to describe Personalized Medicine product scope, market overview, market opportunities, market driving force and market

Read more

Worldwide Cancer Molecular Diagnostics Industry to 2025 – Personalized Medicine and Pharmacogenomics are Driving Growth

DUBLIN, Dec. 1, 2020 /PRNewswire/ — The “Molecular Diagnostics for Cancer – Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025” report has been added to ResearchAndMarkets.com’s offering.

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. The publisher’s latest numbers factor in the different COVID forces, their timing, and their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges, please enquire further for more information.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT

3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 COVID Pandemic
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role

Read more

Star Trek-inspired personalized medicine is on the horizon | Opinion

This article is part of an op-ed series on engineering fields that will change the world by Rutgers School of Engineering faculty.

By Umer Hassan

Real-world innovations – from submarines to self-driving cars – come straight from imaginary worlds of science fiction. Think Star Trek’s handheld tricorder, a medical diagnostic device that made its first appearance in the original TV series. This sci-fi precursor is now changing the face of personalized medicine by taking the tricorder concept to the next level.

Today, diabetics can anticipate a biosensor able to monitor their glucose levels through perspiration. A biosensor implant could detect genetic mutations as they happen, while British researchers are developing a wearable biosensor that will collect data and assess the efficacy of rehabilitation equipment and exercise.

Other biosensors will be able to quickly and inexpensively detect costly and potentially fatal medical conditions such as sepsis and AIDS. Together with Rutgers University colleagues, clinical and industry partners, my lab has been working to solve these global health challenges with new tools that focus on a highly personalized approach to medicine. Since the COVID-19 pandemic began, we are also hoping to apply this technology to fight the coronavirus.

Sepsis – the body’s life-threatening response to infection – is not only deadly, it is the most expensive inpatient medical condition in the United States, with patients who develop sepsis often spending days in intensive care units at a cost of $10,000 a day – or more. Recognizing that sepsis is responsible for as many as 6 million largely preventable deaths a year, the World Health Organization has identified the prevention, diagnosis and management of sepsis as a pressing global health priority.

By applying electrical and computer engineering skills to identify new biomarkers and devise machine-learning algorithms, or artificial intelligence systems, we hope to dramatically improve clinicians’ abilities to diagnose, predict – and ultimately manage – sepsis. Simply reacting to diseases is no longer enough – we need to predict them in order to treat patients in a much smarter way.

To this end, we are building an inexpensive medical device that even minimally trained health care providers can use to accurately diagnosis sepsis. This automated device would cost less than $10 a test and be simple to operate not only in resource-limited settings but anywhere where a rapidly confirmed diagnosis of sepsis is needed.

In sub-Saharan Africa, where only one person in eight is even tested for HIV, many of those infected go undetected until they develop severe complications from the disease. In the near future, cheap, disposable biosensors that are as easy and convenient to use as a home pregnancy test, will detect infections with people living with HIV/AIDS in underdeveloped sub-Saharan African nations. A secondary goal is to develop sensors able to monitor a patient’s response to the antiretroviral therapy they receive.

The positive health and economic impact of such sensors would be felt not only in underdeveloped nations, but also in the United States by reducing the cost of a

Read more

Personalized Medicine Market, 2029

DUBLIN, Nov. 11, 2020 /PRNewswire/ — The “Personalized Medicine – Scientific & Commercial Aspects” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering.

The concept of personalized medicine described in this report remains remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2019-2029.

Profiles of 298 companies involved in developing technologies for personalized medicines, along with 583 collaborations are included.
The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics.

Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results. There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient’s record for the guidance of the physician to individualize the treatment.

Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.A ‘pharmacometabonomic’ approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient’s own cells are considered to be personalized medicines. Vaccines are prepared from individual patient’s tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient’s cells in vitro, prior to reimplantation of these cells in the patient’s body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are

Read more

Global Personalized Medicine Scientific & Commercial Aspects Market Report 2020-2029 with Profiles of 298 Companies Along with 583 Collaborations

Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) — The “Personalized Medicine – Scientific & Commercial Aspects” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering.

The concept of personalized medicine described in this report remains remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2019-2029.

Profiles of 298 companies involved in developing technologies for personalized medicines, along with 583 collaborations are included.
The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics.

Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results. There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient’s record for the guidance of the physician to individualize the treatment.

Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.A ‘pharmacometabonomic’ approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient’s own cells are considered to be personalized medicines. Vaccines are prepared from individual patient’s tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient’s cells in vitro, prior to reimplantation of these cells in the patient’s body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of

Read more

Caliber Raises $2.2M for its Fully Remote and Personalized Fitness Coaching Platform

It’s been easy to gain the Covid-15 during the lockdown, and now that things are slowly opening back up, people are looking for new ways to shed the extra pounds that may have accumulated. Caliber is the fitness coaching platform that offers strength training, nutrition guidance, and a personal fitness coach that’s accessible via text and video messaging to keep you on track.  By pairing Caliber members with fitness experts, Caliber solves the biggest hurdle in getting into and staying in shape – accountability. Members can choose to pay monthly or through a 3 to 6-month subscription and coaches on the platform can supplement their income that comes from training in person.

AlleyWatch caught up with Cofounder and CEO Jared Cluff to learn more about the genesis for the business, how the public’s perception of working out outside of the gym completely flipped, and the company’s recent funding round.

Who were your investors and how much did you raise?

We raised $2.2M for our Seed round.  The round was led by Patricia Nakache at Trinity Ventures based in the Bay Area, with participation from Gaingels, based here in New York.

Tell us about the product or service that Caliber offers.

Caliber is the future of fitness coaching.  We are a comprehensive, fully remote fitness coaching platform that combines a strength-based training methodology with expert human coaching to help our members achieve their fitness goals regardless of their age, experience level, or access to equipment.

Coaching takes place via the Caliber app, where our members can access their personalized training and nutrition plan, interact 1-on-1 with their coach via text and video messaging, complete their workouts and record their body stats, develop healthy habits through weekly Caliber Lessons, and monitor their progress via their Caliber Strength Metrics.

What inspired the start of Caliber?

It’s bizarre, my cofounders and I all share the same story of walking into a gym for the first time as scrawny teenagers, witnessing a bunch of red-faced, grunting dudes stomping around and glaring at each other… and immediately hightailing it out of there.

Yet despite that formative and slightly terrifying first encounter with the gym, we’ve all grown to incorporate fitness – and strength training in particular – as a foundational part of our lives.  The research backs it up, too.  Training for strength is one of the most beneficial forms of exercise.  Recent studies have proven a link between muscle mass and lifespan and have shown that regular strength training can reduce the risk of heart disease by 80% or more.  In addition to improving your cardiovascular health and your longevity, strength training can have a dramatic impact on your mood.  We each can’t start our day without some form of workout, and we’re passionate about sharing the benefits of regular training to people who haven’t yet experienced these benefits firsthand.

At this stage in life for me and my cofounders, it’s not about the aesthetics of being fit, but rather about helping our members

Read more

Trump administration proposals could stymie personalized medicine

“It is more important to know what kind of patient the disease has than to know what kind of disease the patient has.”

Although Hippocrates made this keen observation more than 2,400 years ago, physicians did not have the tools to decipher the biological and environmental factors influencing an individual’s health and well-being until recently.

Since the human genome was finally mapped in 2003, scientists have made tremendous progress in advancing personalized medicine. By tailoring health care to an individual’s biological characteristics, circumstances, and values, personalized medicine can bring unprecedented benefits to patients with rare genetic disorders, cancer, and other diseases.

advertisement

The widely variable effects of the novel coronavirus serve as a painful reminder of the importance of understanding how and why people respond differently to the same disease.

But two recent moves by the Trump administration threaten to turn back the clock on biomedical progress in personalized medicine, which most Americans want, by locking us into a one-size-fits-all world.

advertisement

In an executive order issued in mid-September, President Trump proclaimed his intention to cut drug prices by promising to tie what Medicare pays for prescription medications to their generally lower costs in other countries. These costs are most often based on crude one-size-fits-all health technology assessments.

The order would have a devastating effect on the future of personalized medicine and on patients’ access to lifesaving new drugs. By limiting the return on high-risk investment, it will make it more difficult for biopharmaceutical companies to bet on developing paradigm-changing products, including promising gene and cell-based therapies that may one day be able to cure, not just treat, sickle cell anemia, rare genetic disorders, some cancers, and other diseases.

The executive order was issued less than a month after the Department of Health and Human Services proposed eliminating the Food and Drug Administration’s authority to regulate laboratory-developed tests. That move may unfortunately decrease public confidence in groundbreaking diagnostic tests that have not undergone governmental review just when they are on the precipice of being able to predict cancer and Alzheimer’s disease in advance of the appearance of symptoms, when prevention and treatment plans may be more effective.

Drug pricing could and should encourage drug developers to focus on developing products that will deliver the most benefits to patients and society. Instead, in an effort to end what the president calls “global freeloading,” his executive order on pharmaceutical pricing would link the rates the Centers for Medicare and Medicaid Services pays for drugs covered under Medicare Parts B and D to the lower rates established by other developed countries. These rates are set using health technology assessments that typically do not acknowledge the heterogeneity of treatment effects, despite a rapidly expanding body of scientific evidence demonstrating that the effects of a drug often vary considerably among different subpopulations of patients.

Thus, at a moment when advanced data analytics, artificial intelligence, and real-world evidence are yielding unprecedented insights about which patients should receive which therapies, international reference pricing will rob the

Read more